Related Experiment Video

Updated: Jun 5, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Epcoritamab in Richter Transformation: Insights from a Real-World Case Series

Vanja Zeremski1, Sina Alexandra Beer2, Frederik Damm3

  • 1Otto-von-Guericke-University, Magdeburg, Germany.

Blood Advances
|June 3, 2026
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: Jun 5, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Case report: Eosinophilia as a rare symptom and primary sign of acute lymphoblastic leukemia with translocation (5;14)(q31;q32).

Frontiers in oncology·2026

High-Dimensional Immunophenotyping of Plasma-Derived Small Extracellular Vesicles in Pancreatic Cancer: An Exploratory Proof-of-Principle Study.

Biomolecules·2026

Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany.

Therapeutic advances in medical oncology·2026

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

Lancet (London, England)·2026

Ro 08-2750 increases radiation-induced cytotoxicity in DLBCL by dysregulating the DNA damage response.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Chronic xenogeneic GVHD after CAR T cell therapy limits long-term safety assessment of CAR effects using NSG mouse model.

Blood advances·2026

Modifying quality and equity of care: emerging roles of genetic disease modifiers in β-hemoglobinopathies.

Blood advances·2026

Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200.

Blood advances·2026

Chromatin Accessibility Shapes Developmental-Specific Lineage Plasticity in Hematopoiesis.

Blood advances·2026

ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA.

Blood advances·2026

Real-world investigation of germline predisposition to myelodysplastic syndromes.

Blood advances·2026

Bayesian Additive Regression Trees with Basis-Expanded Functional Covariates.

Pattern analysis and applications : PAA·2026

Influence of [99mTc]Tc-DTPA extravasation on Gates GFR and the effect of antecubital ROI-based dose correction in renal dynamic scintigraphy.

Nuclear medicine review. Central & Eastern Europe·2026

Age and sex differences in the global cancer burden.

Cancer causes & control : CCC·2026

Video-Based Assessment of Operative Complexity in Endometriosis: Associations of AAGL 2021, #Enzian, and rASRM Classifications with Operative Time and Advanced Surgical Procedures.

Journal of minimally invasive gynecology·2026

Association of Annual Caseload and Short Term Outcomes after Elective Open Abdominal Aortic Aneurysm Repair in Germany.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery·2026

Review and guidance for presenting cost-utility analysis with small QALY gains.

Expert review of pharmacoeconomics & outcomes research·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us